Loss of p53 Transcriptional Activity in Hepatocellular Carcinoma Evaluated by Yeast-Based Functional Assay: Comparison with p53 Immunohistochemistry

Human Pathology

Volumn 35, Issue 3, 2004, Pages 350-356

  Mitsumoto, Yasuhide ^a   Nakajima, Tomoki ^b   Marutani, Masumi ^b   Kashiwazaki, Haruhiko ^b   Moriguchi, Michihisa ^b   Kimura, Hiroyuki ^b   Okanoue, Takeshi ^b   Kagawa, Keizo ^b   Tada, Mitsuhiro ^b  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b NONE

Author keywords

Hepatocellular carcinoma; Immunohistochemistry; p53; Transdominance assay; Yeast functional assay

Indexed keywords

MUTANT PROTEIN; PROTEIN P53;

ADULT; AGED; ALLELE; ARTICLE; ASSAY; FEMALE; FRAMESHIFT MUTATION; GENE INACTIVATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MALE; MISSENSE MUTATION; NONSENSE MUTATION; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; YEAST FUNCTIONAL ASSAY;

EID: 1542614990     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2003.09.014     Document Type: Article

References (35)

1. Kastan MB, Zhan Q, el-Deiry WS, et al: A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71:587-597, 1992
2. Kuerbitz SJ, Plunkett BS, Walsh WV, et al: Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci U S A 89:7491-7495, 1992
3. Lowe SW, Schmitt EM, Smith SW, et al: p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362:847-849, 1993
4. Kern SE, Kinzler KW, Bruskin A, et al: Identification of p53 as a sequence-specific DNA-binding protein. Science 252:1708-1711, 1991
5. el-Deiry WS, Kern SE, Pietenpol JA, et al: Definition of a consensus binding site for p53. Nat Genet 1:45-49, 1992
6. Funk WD, Pak DT, Karas RH, et al: A transcriptionally active DNA-binding site for human p53 protein complexes. Mol Cell Biol 12:2866-2871, 1992
7. Kern SE, Pietenpol JA, Thiagalingam S, et al: Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 256:827-830, 1992
8. Scharer E, Iggo R: Mammalian p53 can function as a transcription factor in yeast. Nucleic Acids Res 20:1539-1545, 1992
9. Hainaut P, Soussi T, Shomer B, et al: Database of p53 gene somatic mutations in human tumors and cell lines: Updated compilation and future prospects. Nucleic Acids Res 25:151-157, 1997
10. Beroud C, Verdier F, Soussi T: p53 gene mutation: Software and database. Nucleic Acids Res 24:147-150, 1996
11. Okuda K: Early recognition of hepatocellular carcinoma. Hepatology 6:729-738, 1986
12. Kenmochi K, Sugihara S, Kojiro M: Relationship of histologic grade of hepatocellular carcinoma (HCC) to tumor size, and demonstration of tumor cells of multiple different grades in single small HCC. Liver 7:18-26, 1987
13. Murakami Y, Hayashi K, Hirohashi S, et al: Aberrations of the tumor-suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas. Cancer Res 51:5520-5525, 1991
14. Oda T, Tsuda H, Scarpa A, et al: p53 gene mutation spectrum in hepatocellular carcinoma. Cancer Res 52:6358-6364, 1992
15. Hayashi H, Sugio K, Matsumata T, et al: The clinical significance of p53 gene mutation in hepatocellular carcinomas from Japan. Hepatology 22:1702-1707, 1995
16. Kimura H, Kagawa K, Nakajima T: Immunohistochemical study on p53 expression in hepatocellular carcinoma. Acta Hepatologica Japonica 34:606-610, 1993
17. Unger T, Nau MM, Segal S, et al: p53: A transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer. EMBO J 11:1383-1390, 1992
18. Levine AJ, Momand J, Finlay CA: The p53 tumour-suppressor gene. Nature 351:453-456, 1991
19. Vogelstein B, Kinzler KW: p53 function and dysfunction. Cell 70:523-526, 1992
20. Orita M, Suzuki Y, Sekiya T, et al: Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 5:874-879, 1989
21. Tenaud C, Negoescu A, Labat-Moleur F, et al: p53 immunolabeling in archival paraffin-embedded tissues: Optimal protocol based on microwave heating for eight antibodies on lung carcinomas. Mod Pathol 7:853-859, 1994
22. Nagao T, Kondo F, Sato T, et al: Immunohistochemical detection of aberrant p53 expression in hepatocellular carcinoma: Correlation with cell proliferative activity indices, including mitotic index and MIB-1 immunostaining. Hum Pathol 26:326-333, 1995
23. Pomerantz J, Schreiber-Agus N, Liegeois NJ, et al: The Ink4a tumor-suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92:713-723, 1998
24. Zhang Y, Xiong Y, Yarbrough WG: ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor-suppression pathways. Cell 92:725-734, 1998
25. Kashiwazaki H, Tonoki H, Tada M, et al: High frequency of p53 mutations in human oral epithelial dysplasia and primary squamous cell carcinoma detected by yeast functional assay. Oncogene 15:2667-2674, 1997
26. Flaman JM, Frebourg T, Moreau V, et al: A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci U S A 92:3963-3967, 1995
27. Tada M, Iggo RD, Ishii N, et al: Clonality and stability of the p53 gene in human astrocytic tumor cells: Quantitative analysis of p53 gene mutations by yeast functional assay. Int J Cancer 67:447-450, 1996
28. Marutani M, Tonoki H, Tada M, et al: Dominant-negative mutations of the tumor-suppressor p53 relating to early onset of glioblastoma multiforme. Cancer Res 59:4765-4769, 1999
29. Kato H, Kato S, Kumabe T, et al: Functional evaluation of p53 and PTEN gene mutations in gliomas. Clin Cancer Res 6:3937-3943, 2000
30. Okuda K, Musha H, Nakajima Y, et al: Clinicopathological features of encapsulated hepatocellular carcinoma. A study of 26 cases. Cancer 40:1240-1245, 1977
31. Tada M, Iggo RD, Waridel F, et al: Reappraisal of p53 mutations in human malignant astrocytic neoplasms by p53 functional assay: Comparison with conventional structural analyses. Mol Carcinog 18:171-176, 1997
32. Takahashi M, Tonoki H, Tada M, et al: Distinct prognostic values of p53 mutations and loss of estrogen receptor and their cumulative effect in primary breast cancers. Int J Cancer 89:92-99, 2000
33. Rolley N, Butcher S, Milner J: Specific DNA binding by different classes of human p53 mutants. Oncogene 11:763-770, 1995
34. Hall PA, Lane DP: p53 in tumour pathology: Can we trust immunohistochemistry? Revisited! J Pathol 172:1-4, 1994
35. Ueda H, Ullrich SJ, Gangemi JD, et al: Functional inactivation but not structural mutation of p53 causes liver cancer. Nat Genet 9:41-47, 1995